Multiple myeloma and cardiovascular risk (a literature review)
Multiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2020-11-01
|
| Series: | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
| Subjects: | |
| Online Access: | http://pharmed.zsmu.edu.ua/article/view/216234/216815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850056024063475712 |
|---|---|
| author | B. B. Samura M. O. Panasenko S. Ya. Dotsenko |
| author_facet | B. B. Samura M. O. Panasenko S. Ya. Dotsenko |
| author_sort | B. B. Samura |
| collection | DOAJ |
| description | Multiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities such as cardiomyopathy and heart failure caused by cardiac amyloidosis and/or anemia. Heart dysfunction occuring after cytostatic drugs and monoclonal antibodies intake may act as a limiting factor in multiple myeloma treatment. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death.
Advances in pharmacotherapy for MM, such as the introduction of immunomodulators, proteasome inhibitors, and monoclonal antibodies, have dramatically improved life expectancy, but new agent classes are associated with adverse effects, including cardiovascular events.
The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy.
However, with careful risk assessment, monitoring, and prophylactic therapy, many of these cardiovascular complications can be managed or treated successfully. It is important to detect cardiovascular toxicity before clinical signs of heart and vessel disturbance appear. The role of markers in elicitation of cardiovascular events risk group is still uncertain.
Early definition of risk factors for prognosis of cardiovascular events appearing after polychemotherapy of multiple myeloma is an important and yet unsolved problem. |
| format | Article |
| id | doaj-art-a5e42e4eea784a0d9561bdd08ecf1c6d |
| institution | DOAJ |
| issn | 2306-8094 2409-2932 |
| language | English |
| publishDate | 2020-11-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
| spelling | doaj-art-a5e42e4eea784a0d9561bdd08ecf1c6d2025-08-20T02:51:48ZengZaporizhzhia State Medical and Pharmaceutical UniversityAktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki2306-80942409-29322020-11-0113343744410.14739/2409-2932.2020.3.216234Multiple myeloma and cardiovascular risk (a literature review)B. B. Samura0M. O. Panasenko1S. Ya. Dotsenko2Zaporizhzhia State Medical University, UkraineZaporizhzhia State Medical University, UkraineZaporizhzhia State Medical University, UkraineMultiple myeloma is a plasma cell clonal malignancy that accounts for 10 % of hematological cancers. It predominantly affects elderly people; median age at diagnosis is 70 years. Consequently, many patients with MM have cardiovascular comorbidities or risk factors. MM can cause cardiac comorbidities such as cardiomyopathy and heart failure caused by cardiac amyloidosis and/or anemia. Heart dysfunction occuring after cytostatic drugs and monoclonal antibodies intake may act as a limiting factor in multiple myeloma treatment. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death. Advances in pharmacotherapy for MM, such as the introduction of immunomodulators, proteasome inhibitors, and monoclonal antibodies, have dramatically improved life expectancy, but new agent classes are associated with adverse effects, including cardiovascular events. The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. However, with careful risk assessment, monitoring, and prophylactic therapy, many of these cardiovascular complications can be managed or treated successfully. It is important to detect cardiovascular toxicity before clinical signs of heart and vessel disturbance appear. The role of markers in elicitation of cardiovascular events risk group is still uncertain. Early definition of risk factors for prognosis of cardiovascular events appearing after polychemotherapy of multiple myeloma is an important and yet unsolved problem.http://pharmed.zsmu.edu.ua/article/view/216234/216815multiple myelomacardiovascular eventschemotherapydiagnosticsprognostic factors |
| spellingShingle | B. B. Samura M. O. Panasenko S. Ya. Dotsenko Multiple myeloma and cardiovascular risk (a literature review) Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki multiple myeloma cardiovascular events chemotherapy diagnostics prognostic factors |
| title | Multiple myeloma and cardiovascular risk (a literature review) |
| title_full | Multiple myeloma and cardiovascular risk (a literature review) |
| title_fullStr | Multiple myeloma and cardiovascular risk (a literature review) |
| title_full_unstemmed | Multiple myeloma and cardiovascular risk (a literature review) |
| title_short | Multiple myeloma and cardiovascular risk (a literature review) |
| title_sort | multiple myeloma and cardiovascular risk a literature review |
| topic | multiple myeloma cardiovascular events chemotherapy diagnostics prognostic factors |
| url | http://pharmed.zsmu.edu.ua/article/view/216234/216815 |
| work_keys_str_mv | AT bbsamura multiplemyelomaandcardiovascularriskaliteraturereview AT mopanasenko multiplemyelomaandcardiovascularriskaliteraturereview AT syadotsenko multiplemyelomaandcardiovascularriskaliteraturereview |